CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position
CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS PROVIDES BUSINESS UPDATE, REAFFIRMS 2026 TOTAL REVENUE GUIDANCE, AND REPORTS THIRD Quarter Cash Position Parsippany, NJ – November 2, 2026 – CorMedix Therapeutics (Nasdaq: CRMD) today provided a business update in advance of a conference call ex
How this was made
The 30-second read
Why it matters
The reaffirmation maintains current valuation assumptions; no new upside or downside is introduced.
Market read
The update is a modest, low‑volatility event for traders; relevance is short‑term.
What to watch
Potential volatility in CMS reimbursement methodology and utilization trends could affect future revenue.
CorMedix reaffirms 2026 total revenue guidance of between $325 million and $345 million and reports approximately $355 million of cash and cash equivalents as of September 30, 2026.
The company reaffirmed full-year revenue guidance and reported a substantial cash position, but did not provide third-quarter revenue, profitability, cash flow, or other complete quarterly financial results ahead of its expected November 12, 2026 conference call.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Cash and cash equivalents as of September 30, 2026other | approximately $355 million | – | – |
full-year 2026 outlook
- Revenuebetween $325 million and $345 million
- NoteThe Q1 2027 DefenCath® post-TDAPA Add-on is $8.32 per dialysis session.
- NoteThe Company anticipates that the DefenCath Add-on will decline in Q2 of 2027 compared to Q1, but increase in Q3 and/or Q4 of 2027 compared to Q2.
- NoteThe Company believes that the Add-on rate for all four quarters in 2027 will exceed the current rate of $2.37.
- NoteThe Company believes that the average Add-on rate for all four quarters in 2027 will equate to more than 2x the current rate of $2.37.
What drove it
- CMS released the 2027 ESRD PPS final rule on October 28, 2026, providing a post-TDAPA Add-on for DefenCath® of $8.32 per dialysis session for Q1 of 2027.
- The Q1 2027 Add-on of $8.32 is within the Company’s previously guided range of 3x-5x higher than the current $2.37 in effect for the third and fourth quarters of 2026.
- CorMedix cited its evaluation of sales data, DefenCath fee-for-service utilization insights, and contractual arrangements with customers in discussing the anticipated 2027 Add-on trajectory.
Concerns
- Complete quarterly financial performance was not provided; the Company expects to discuss financial results on November 12, 2026.
- The Company expects the DefenCath Add-on to decline in Q2 of 2027 compared to Q1.
- The 2027 Add-on estimates depend on utilization and pricing data, DefenCath maintaining fee-for-service utilization in line with current trends, and CMS’s application of certain utilization data.
- The Company stated that increased reimbursement to dialysis facilities may not result in corresponding increases in realized pricing, product utilization, or revenue.
- The filing cites continued pricing pressures and payer actions affecting pricing, reimbursement, and patient access to pharmaceuticals as risks.
What to watch
- Complete third-quarter financial results and additional business updates expected to be discussed on November 12, 2026.
- DefenCath fee-for-service utilization and realized pricing.
- CMS application of utilization data in calculating quarterly 2027 Add-on adjustments.
- Whether the 2027 Add-on declines in Q2 and subsequently increases in Q3 and/or Q4 as anticipated.
- Execution against full-year 2026 total revenue guidance of between $325 million and $345 million.
Balance sheet and cash flow
- Unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million.
Analysis
This filing is a business update rather than a complete quarterly earnings release. CorMedix reported unaudited cash and cash equivalents of approximately $355 million as of September 30, 2026, while stating that complete quarterly financial performance will be discussed on an expected November 12, 2026 conference call. The absence of reported third-quarter revenue, earnings, margins, operating expenses, and cash flow prevents an assessment of reported operating performance for the period.
The principal financial update is the reaffirmation of full-year 2026 total revenue guidance of between $325 million and $345 million. The company described this as a reaffirmation of its August 2026 guidance, but the previous outlook document was not provided. No segment revenue, product revenue, utilization volume, or pricing realization was disclosed in this filing.
The major business development is CMS’s October 28, 2026 release of the 2027 ESRD PPS final rule. It establishes a Q1 2027 post-TDAPA Add-on for DefenCath® of $8.32 per dialysis session. CorMedix stated that this amount is within its previously guided range of 3x-5x higher than the current $2.37 rate in effect for the third and fourth quarters of 2026. The company also expects the Add-on to decline in Q2 of 2027 versus Q1, then increase in Q3 and/or Q4 versus Q2, subject to CMS’s application of utilization data.
Management emphasized that third-party projections of future quarterly Add-on adjustments face significant uncertainty without access to relevant utilization and pricing data. It also cautioned that higher dialysis-facility reimbursement may not translate into increased realized pricing, utilization, or revenue. The key operating issue for the upcoming full earnings update is whether reported DefenCath demand and realized revenue support the reiterated full-year range, alongside further detail on the expected 2027 reimbursement trajectory.
Not in the filing
stated, not guessed- Third-quarter 2026 total revenue.
- Third-quarter 2026 prior-year and prior-quarter total revenue.
- Third-quarter 2026 total revenue growth.
- Segment or product revenue.
- Gross profit and gross margin.
- Operating expenses.
- Operating income or loss.
- Net income or loss.
- GAAP earnings or loss per share.
- Non-GAAP earnings or loss per share.
- Operating cash flow.
- Free cash flow.
- Debt.
- Capital returns, including share repurchases and dividends.
- Cash and cash equivalents comparison with prior year or prior quarter.
- Third-quarter 2026 financial results.
- Named executive quotes.
- Previous outlook document needed to compare reported actual results with prior guidance.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was checked against the filing text, and a metric whose value, prior period and change do not add up is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is a Regulation FD disclosure providing a business update ahead of the Q3 earnings call.
Ticker impact
CorMedix reaffirmed its 2026 total revenue guidance of $325M‑$345M and disclosed $355M cash on hand.
likely limited movement as guidance is reaffirmed without surprise.
Investors already priced in the guidance range; the new cash figure may provide slight support but no directional catalyst.
Market effects
Reaffirmed dialysis‑related revenue guidance may reinforce outlook for the renal‑care sector.
US biotech investors may view the update as a stability signal.
Limited; impact confined to CorMedix and its niche market.
Counterpoint
If CMS further raises the add‑on rates, the reaffirmed guidance could be seen as undervalued.
Key entities
- CompanyCorMedix Therapeutics
Biopharma focused on dialysis‑related products.
- RegulatorCMS
U.S. Centers for Medicare & Medicaid Services, issuer of the ESRD PPS add‑on.
